Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated influenza vaccine trivalent types A and B (split virion)
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A seasonal influenza vaccine that protects against three different influenza viruses - one influenza A(H1N1) virus, one influenza A(H3N2) virus, and one influenza B virus (typically from the Victoria lineage). The vaccine is produced using a split virion technique, where influenza viruses are grown in embryonated chicken eggs, harvested, and then inactivated with formaldehyde before being chemically disrupted to produce a "split virus."
- Brand names
- VaxigripFLUZONE High-DoseAfluriaAgrippalFluadFlucelvax
Beyond the preview
Go deeper on inactivated influenza vaccine trivalent types A and B (split virion).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated influenza vaccine trivalent types A and B (split virion).